Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;8(1):183-187.
doi: 10.1016/j.ekir.2022.10.002. Epub 2022 Oct 11.

COVID-19 Severity in Kidney Transplant Recipients According to Their Postvaccination Serological Assessment

Christophe Masset  1   2 , Claire Garandeau  1 , Aurélie Houzet  1 , Delphine Kervella  1   2 , Simon Ville  1   2 , Diego Cantarovich  1 , Alice Leclech  1 , Claire Leman  1 , Raphael Gaisne  1 , Cécile Guillot-Gueguen  1 , Océane Salomon  1 , Clarisse Kerleau  1   2 , Magali Giral  1   2 , Jacques Dantal  1   2 , Gilles Blancho  1   2 ; Nantes DIVAT Consortium
Collaborators, Affiliations

COVID-19 Severity in Kidney Transplant Recipients According to Their Postvaccination Serological Assessment

Christophe Masset et al. Kidney Int Rep. 2023 Jan.
No abstract available

Keywords: Covid-19; kidney transplant recipient; mRNA vaccine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) Humoral response following SARS-CoV-2 vaccination in included COVID-19 patients from the 3 defined groups expressed by IgG antispike (BAU/ml). (b) Humoral response following SARS-Cov-2 vaccination in a cohort control of vaccinated patients (3 doses) without COVID-19 infection expressed by IgG antispike (BAU/ml). (c) Repartition of the patients depending on their postvaccination humoral response in the COVID-19 studied cohort and in the non-COVID-19 control cohort. (d) Survival without hospitalization depending on the vaccination status and the postvaccination serological assessment in the studied cohort. (e) Survival without intensive care unit hospitalization depending on the vaccination status and the postvaccination serological assessment in the studied cohort. (f) Survival without death depending on the vaccination status and the postvaccination serological assessment in the studied cohort. (g) Symptoms and major complications following COVID-19 depending on the vaccination status and the postvaccination serological assessment. (h) Representation of monthly new cases of COVID-19 in our center with the presumed different variants of concern based on the local epidemiology. (i) Representation of monthly new COVID-19 hospitalizations in our center with the presumed different variants of concern based on the local epidemiology. ∗represents a significant difference between NO VAC and LOW POS groups; §represents a significant difference between NO VAC and HIGH POS groups; ¥represents a significant difference between SERO NEG and LOW POS groups; £represents a significant difference between SERO NEG and HIGH POS groups; one symbol refers to a P-value < 0.05; 2 symbols to a P-value < 0.01 and 3 symbols to a P-value < 0.001. HIGH POS, strong humoral response; LOW POS, weak humoral response; SERO NEG, vaccinated without humoral response;
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Caillard S., Anglicheau D., Matignon M., et al. An initial report from the French SOT COVID Registry suggests high mortality due to Covid-19 in recipients of kidney transplants. Kidney Int. 2020;98:1549–1558. doi: 10.1016/j.kint.2020.08.005. - DOI - PMC - PubMed
    1. Masset C., Kerleau C., Garandeau C., et al. A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response. Kidney Int. 2021;100:1132–1135. doi: 10.1016/j.kint.2021.08.017. - DOI - PMC - PubMed
    1. Benotmane I., Gautier G., Perrin P., et al. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses. JAMA. 2021;326:1063–1065. doi: 10.1001/jama.2021.12339. - DOI - PMC - PubMed
    1. Caillard S., Chavarot N., Bertrand D., et al. Occurrence of severe COVID-19 in vaccinated transplant patients. Kidney Int. 2021;100:477–479. doi: 10.1016/j.kint.2021.05.011. - DOI - PMC - PubMed
    1. Feng S., Phillips D.J., White T., et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27:2032–2040. doi: 10.1038/s41591-021-01540-1. - DOI - PMC - PubMed

LinkOut - more resources